Fri, May 9, 12:26 PM (14 days ago)
CVRx, Inc. (CVRX) reported its quarterly financial health for the period ending March 31, 2025. The company, focused on developing and commercializing neuromodulation solutions for cardiovascular diseases, saw a 15% increase in revenue to $12.3 million, driven by growth in the U.S. and Europe. Gross profit rose by 13% to $10.3 million, with a slight decrease in gross margin from 85% to 84%. Operating expenses decreased by 24%, primarily due to a significant reduction in non-cash stock-based compensation. However, the company reported a net loss of $13.8 million, an improvement from the $22.2 million loss in the previous year. Cash and cash equivalents stood at $102.7 million, with net cash used in operating activities at $12.8 million. CVRx continues to invest in its U.S. commercial infrastructure and expects to incur significant losses in the near future. The company's future performance is subject to uncertainties, including market acceptance, reimbursement levels, and regulatory compliance. CVRx remains focused on expanding its sales force, increasing physician and patient awareness, and developing clinical evidence to support Barostim's benefits.